secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001558370-23-010412
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed
--------------------------------------------------------------------------------

- Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.
- Dr. Melissa Palmer appointed interim Chief Medical Officer; she has NASH and liver disease expertise.
- Dr. Salah Kivlighn joins as clinical and strategic advisor; 30+ years industry experience including at Merck and Kite Pharma.
- Company priorities: lift HIV clinical hold on leronlimab, advance NASH phase 2b trial, explore strategic opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/cydy-20230518x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer